Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS G12S||renal pelvis transitional cell carcinoma||predicted - sensitive||Tipifarnib||Case Reports/Case Series||Actionable||In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, a patient with renal pelvis transitional cell carcinoma harboring HRAS G12S achieved a partial response (PMID: 32636318; NCT02535650).||32636318|
|HRAS G12S||head and neck squamous cell carcinoma||predicted - sensitive||Tipifarnib||Preclinical - Pdx||Actionable||In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring HRAS G12S was sensitive to treatment with Zarnestra (tipifarnib), demonstrating inhibition of tumor growth, decreased cell proliferation, and reduced Erk activity (PMID: 32727882).||32727882|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|